Genentech, a member of the Roche Group (RHHBY.PK), announced positive results from the pivotal Phase III GALLIUM study in people with previously untreated follicular lymphoma, the most common type of indolent (slow-growing) non-Hodgkin's lymphoma or ... RTTNews.com, 1 day ago
2 images for "genentech rank"
On May 12, Zacks Investment Research upgraded Kite Pharma, Inc . KITE to a Zacks Rank #3 (Hold) from a Zacks Rank #4 (Sell) Why the Upgrade? Kite reported results for the first quarter 2016 on May 9. Kite's track record has been satisfactory so ...Yahoo! Finance UK and Ireland, 2 weeks ago
Kite Pharma, Inc . KITE announced that it has entered into a collaboration agreement with Roche Holding's RHHBY Genentech for its immunotherapy candidate, KTE-C19. Per the terms of the agreement, the companies will collaborate to evaluate the ...Yahoo! Singapore, 2 months ago
More from: Nasdaq, Zacks.com...and 1 other sources
UCSF-Led Study Suggests Asthma Treatment Guidelines Due for Update Children aged 6 and under with intermittent wheezing triggered by colds may not need to take inhaled steroids on a daily basis to limit the flare-ups that can result in emergency ...Health Canal, 1 day ago
/PRNewswire/ -- Entelo, the leading provider of enterprise software for data-driven recruiting, today announced that it has closed a $12 million Series B financing round led by venture capital firm Shasta Ventures. Existing investor Battery Ventures ...TickerTech.com, 3 days ago ntelo Raises $12 Million in Series B Funding to Bring Data-Driven Recruiting to the Enterprise HRO Today, 2 days ago
Exelixis Announces Results from Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Exelixis to consult with regulatory ...BioSpace, 4 days ago Exelixis Announces Results from Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Benzinga.com, 4 days ago EXELIXIS : Announces Results from Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma 4 Traders, 4 days ago
CHUGAI PHARMACEUTICAL : Anti-Cancer Agent Avastin®, Obtained Approval for Additional Indication of Advanced or Recurrent Cervical Cancer
-- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that it gained approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) on May 23, 2016, for 'advanced or recurrent cervical cancer,' as new additional indication for the ...4 Traders, 5 days ago
The U.S. Food and Drug Administration said that it approved Tecentriq or atezolizumab to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this ...RTTNews.com, 1 week ago
By a News Reporter-Staff News Editor at Biotech Week Nurix, Inc., a private drug discovery company, announced the appointments of David Lacey, M.D., and Perry Karsen to the company's board of directors. In addition, Tim Kutzkey, Ph.D., a partner at ...Pharmacy Choice, 1 week ago
Intrexon Corp (NYSE: XON ) Q1 2016 Earnings Conference Call May 10, 2016, 05:30 PM ET Executives Christopher Basta - Vice President, Investor Relations Randal Kirk - Chairman and Chief Executive Officer Joel Liffmann - Senior Vice ...Seeking Alpha, 2 weeks ago
on your WebpageAdd Widget >Get your members hooked!